{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:11:52Z","timestamp":1779919912662,"version":"3.53.1"},"reference-count":67,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministerio de Ciencia e Innovaci\u00f3n","award":["PID2021-127863OB-I00"],"award-info":[{"award-number":["PID2021-127863OB-I00"]}]},{"name":"Ministerio de Ciencia e Innovaci\u00f3n","award":["PID2021-127693OB-100"],"award-info":[{"award-number":["PID2021-127693OB-100"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Proximity-induced pharmacology (PIP) for amyloid-related diseases is a cutting-edge approach to treating conditions such as Alzheimer\u2019s disease and other forms of dementia. By bringing small molecules close to amyloid-related proteins, these molecules can induce a plethora of effects that can break down pathogenic proteins and reduce the buildup of plaques. One of the most promising aspects of this drug discovery modality is that it can be used to target specific types of amyloid proteins, such as the beta-amyloid protein that is commonly associated with Alzheimer\u2019s disease. This level of specificity could allow for more targeted and effective treatments. With ongoing research and development, it is hoped that these treatments can be refined and optimized to provide even greater benefits to patients. As our understanding of the underlying mechanisms of these diseases continues to grow, proximity-induced pharmacology treatments may become an increasingly important tool in the fight against dementia and other related conditions.<\/jats:p>","DOI":"10.3390\/cells13050449","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T08:03:47Z","timestamp":1709539427000},"page":"449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Proximity-Induced Pharmacology for Amyloid-Related Diseases"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7971-6540","authenticated-orcid":false,"given":"Andrea","family":"Bertran-Mostazo","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Biomedicine (IBUB), University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel\u0117","family":"Putri\u016bt\u0117","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"\u00c1lvarez-Berbel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-9886","authenticated-orcid":false,"given":"Maria","family":"Busquets","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Nanoscience and Nanotechnology (IN<sup>2<\/sup>UB), University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1702-0369","authenticated-orcid":false,"given":"Carles","family":"Galdeano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Biomedicine (IBUB), University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-767X","authenticated-orcid":false,"given":"Alba","family":"Espargar\u00f3","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Nanoscience and Nanotechnology (IN<sup>2<\/sup>UB), University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-2362","authenticated-orcid":false,"given":"Raimon","family":"Sabate","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Nanoscience and Nanotechnology (IN<sup>2<\/sup>UB), University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein Misfolding, Functional Amyloid, and Human Disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1146\/annurev-biochem-061516-045037","article-title":"Oxidative Stress","volume":"86","author":"Sies","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/d41573-023-00044-6","article-title":"Proximity-inducing drugs get closer","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hyun, S., and Shin, D. (2021). Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases. Life, 11.","DOI":"10.3390\/life11070607"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","article-title":"Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy","volume":"65","author":"Fang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.apsb.2022.03.019","article-title":"Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101616","DOI":"10.1016\/j.arr.2022.101616","article-title":"Targeted protein degraders march towards the clinic for neurodegenerative diseases","volume":"78","author":"Kumar","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Li, F., Aljahdali, I.A.M., and Ling, X. (2022). Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein\u2013Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116206"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/ange.201507978","article-title":"Niedermolekulare PROTACs: Neue Wege zum Abbau von Proteinen","volume":"128","author":"Toure","year":"2016","journal-title":"Angew. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"bqaa224","DOI":"10.1210\/endocr\/bqaa224","article-title":"Mini-Review Genome-Wide Estrogen Receptor Activity in Breast Cancer","volume":"162","author":"Farcas","year":"2021","journal-title":"Endocrinology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_15","first-page":"1","article-title":"PROTACs: Great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1021\/acsmedchemlett.0c00423","article-title":"Simultaneous Inhibition of SIRT2 Deacetylase and Defatty-Acylase Activities via a PROTAC Strategy","volume":"11","author":"Hong","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative Tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chembiol.2016.02.016","article-title":"Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation","volume":"23","author":"Chu","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/pro.5560071011","article-title":"Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease","volume":"7","author":"Taremi","year":"1998","journal-title":"Protein Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e45457","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"eLife"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"801179","DOI":"10.3389\/fncel.2022.801179","article-title":"Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy","volume":"16","author":"Silva","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acsmedchemlett.9b00083","article-title":"Treatment of Alzheimer\u2019s by PROTAC-Tau Protein Degradation","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"ref_24","unstructured":"(2024, January 10). Arvinas, \u201cNeuroscience\u201d. Available online: https:\/\/www.arvinas.com\/research-and-development\/neuroscience\/."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson\u2019s Disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","article-title":"PROTAC Compounds Targeting \u03b1-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer\u2019s and Parkinson\u2019s Diseases","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wen, T., Chen, J., Zhang, W., and Pang, J. (2023). Design, Synthesis and Biological Evaluation of \u03b1-Synuclein Proteolysis-Targeting Chimeras. Molecules, 28.","DOI":"10.3390\/molecules28114458"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnmol.2019.00025","article-title":"Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis","volume":"12","author":"Prasad","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-023-00921-7","article-title":"Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera","volume":"30","author":"Tseng","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2206","DOI":"10.1038\/cddis.2016.104","article-title":"GSK-3\u03b2-induced Tau pathology drives hippocampal neuronal cell death in Huntington\u2019s disease: Involvement of astrocyte\u2013neuron interactions","volume":"7","author":"Tirolo","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/hipo.20805","article-title":"GSK3\u03b2 overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus","volume":"21","author":"Hernandez","year":"2011","journal-title":"Hippocampus"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nature01640","article-title":"GSK-3\u03b1 regulates production of Alzheimer\u2019s disease amyloid-\u03b2 peptides","volume":"423","author":"Phiel","year":"2003","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112949","DOI":"10.1016\/j.ejmech.2020.112949","article-title":"PROTACs suppression of GSK-3\u03b2, a crucial kinase in neurodegenerative diseases","volume":"210","author":"Jiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/acschemneuro.3c00096","article-title":"PROTAC-Induced Glycogen Synthase Kinase 3\u03b2 Degradation as a Potential Therapeutic Strategy for Alzheimer\u2019s Disease","volume":"14","author":"Guardigni","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood\u2013Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_36","unstructured":"(2024, January 10). Origami Therapeutics, \u201cOrigami Therapeutics\u201d. Available online: https:\/\/origamitherapeutics.com\/huntingtons\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jb\/mvac041","article-title":"Targeted protein degradation and drug discovery","volume":"172","author":"Naito","year":"2022","journal-title":"J. Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fchem.2019.00849","article-title":"Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs","volume":"7","author":"Naito","year":"2019","journal-title":"Front. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1248\/cpb.c18-00567","article-title":"Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)","volume":"67","author":"Ohoka","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/14756366.2022.2074414","article-title":"Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents","volume":"37","author":"Wang","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and Neuropathology of Huntington\u2019s Disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1002\/anie.201706529","article-title":"Discovery of Small Molecules that Induce the Degradation of Huntingtin","volume":"56","author":"Tomoshige","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Yamashita, H., Tomoshige, S., Nomura, S., Ohgane, K., Hashimoto, Y., and Ishikawa, M. (2020). Application of protein knockdown strategy targeting \u03b2-sheet structure to multiple disease-associated polyglutamine proteins. Bioorganic Med. Chem., 28.","DOI":"10.1016\/j.bmc.2019.115175"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/j.jmb.2019.10.013","article-title":"Selective Autophagy Receptors in Neuronal Health and Disease","volume":"432","author":"Conway","year":"2020","journal-title":"J. Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.apsb.2021.02.016","article-title":"Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson\u2019s disease","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_46","first-page":"1","article-title":"The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system","volume":"13","author":"Ji","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Shaltiel-Karyo, R., Frenkel-Pinter, M., Egoz-Matia, N., Frydman-Marom, A., Shalev, D.E., Segal, D., and Gazit, E. (2010). Inhibiting \u03b1-Synuclein Oligomerization by Stable Cell-Penetrating \u03b2-Synuclein Fragments Recovers Phenotype of Parkinson\u2019s Disease Model Flies. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013863"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/15548627.2023.2274711","article-title":"Targeted degradation of SNCA\/\u03b1-synuclein aggregates in neurodegeneration using the AUTOTAC chemical platform","volume":"20","author":"Lee","year":"2023","journal-title":"Autophagy"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Jarosi\u0144ska, O.D., and R\u00fcdiger, S.G.D. (2021). Molecular Strategies to Target Protein Aggregation in Huntington\u2019s Disease. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.769184"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.1101262","article-title":"Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid \u00df Aggregation","volume":"306","author":"Gestwicki","year":"2004","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e202217246","DOI":"10.1002\/anie.202217246","article-title":"Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation","volume":"62","author":"Xie","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"40362","DOI":"10.1039\/C7RA05347A","article-title":"Hydrophobic tagging-mediated degradation of Alzheimer\u2019s disease related Tau","volume":"7","author":"Gao","year":"2017","journal-title":"RSC Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1073\/pnas.0912417107","article-title":"TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration","volume":"107","author":"Wils","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bioorg.2018.11.042","article-title":"TDP-43 specific reduction induced by Di-hydrophobic tags conjugated peptides","volume":"84","author":"Gao","year":"2019","journal-title":"Bioorganic Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A Method for the Acute and Rapid Degradation of Endogenous Proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chen, G., Kong, Y., Li, Y., Huang, A., Wang, C., Zhou, S., Yang, Z., Wu, Y., Ren, J., and Ying, T. (2021). A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment. Biomolecules, 11.","DOI":"10.3390\/biom11101512"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3389\/fimmu.2019.02049","article-title":"TRIM21\u2014From Intracellular Immunity to Therapy","volume":"10","author":"Foss","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bhaduri, U., and Merla, G. (2021). Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity. Cells, 10.","DOI":"10.3390\/cells10051015"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnmol.2014.00042","article-title":"Protein phosphorylation in neurodegeneration: Friend or foe?","volume":"7","author":"Tenreiro","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"ref_60","first-page":"1","article-title":"A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies","volume":"6","author":"Zheng","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1021\/jacs.2c11706","article-title":"Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality","volume":"145","author":"Hu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1039\/D2CS00197G","article-title":"Chasing molecular glue degraders: Screening approaches","volume":"51","author":"Domostegui","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuroscience.2015.08.042","article-title":"14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3\u03b8 overexpression promotes recovery in the MPTP mouse model of Parkinson\u2019s disease","volume":"307","author":"Ding","year":"2015","journal-title":"Neuroscience"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1073\/pnas.1817567116","article-title":"Stabilization of amyloidogenic immunoglobulin light chains by small molecules","volume":"116","author":"Morgan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17460441.2021.1915979","article-title":"Is PROTAC technology really a game changer for central nervous system drug discovery?","volume":"16","author":"Farrell","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acscentsci.3c00015","article-title":"Proximity-Induced Nucleic Acid Degrader (PINAD) Approach to Targeted RNA Degradation Using Small Molecules","volume":"9","author":"Mikutis","year":"2023","journal-title":"ACS Cent. Sci."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/5\/449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:49Z","timestamp":1760105329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/5\/449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":67,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cells13050449"],"URL":"https:\/\/doi.org\/10.3390\/cells13050449","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}